Ennovabio is a pharmaceutical research and development company based in Shanghai, China. Established in 2017, the company is dedicated to the development of novel drugs in the clinical stage, focusing on the research and innovation of 1. 1 category new drugs.

With a team of experienced drug development experts, Ennovabio aims to provide maximum therapeutic value to patients by starting from the source of new drug development. The company's strategy revolves around deep understanding and utilization of innovative technology platforms to seek unique opportunities and develop characteristic new drug development models. Ennovabio also focuses on common diseases in China, validating clinical concepts through early-stage development.

Additionally, they establish external strategic collaborations to expand their research and development capabilities and pipeline. The team at Ennovabio consists of highly qualified professionals, with approximately 36% holding doctoral degrees and 69% holding master's degrees or above. A significant percentage of their employees have backgrounds from renowned domestic and overseas pharmaceutical companies, bringing rich experience in drug development.

Ennovabio's expertise lies in scientific research, development pipeline, core technological capabilities, rapid navigation, project collaboration, and news delivery. For more information, contact Ennovabio at (+86) 021-50821573 or visit their website